HC Wainwright Issues Optimistic Forecast for HOWL Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Werewolf Therapeutics from ($0.47) to ($0.41), with full-year earnings projected at ($1.56) per share.
• Wedbush decreased its price target for Werewolf Therapeutics from $8.00 to $6.00 while maintaining an "outperform" rating for the company.
• Hedge funds have been increasing their positions in Werewolf Therapeutics, with significant purchases from firms like D.E. Shaw & Co. and Jane Street Group LLC.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for shares of Werewolf Therapeutics in a research report issued on Thursday, August 14th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.41) per share for the quarter, up from their prior estimate of ($0.47). The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Werewolf Therapeutics' Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.16) EPS and FY2029 earnings at ($0.70) EPS.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10.

Several other analysts have also recently commented on the stock. JMP Securities lowered their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating for the company in a research note on Thursday. Wedbush lowered their price objective on Werewolf Therapeutics from $8.00 to $6.00 and set an "outperform" rating for the company in a research report on Friday, May 9th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Werewolf Therapeutics presently has an average rating of "Buy" and an average target price of $8.00.

Werewolf Therapeutics Trading Up 2.0%

Shares of NASDAQ:HOWL traded up $0.0250 during trading on Monday, reaching $1.2650. The stock had a trading volume of 38,718 shares, compared to its average volume of 359,925. The company has a quick ratio of 8.09, a current ratio of 5.30 and a debt-to-equity ratio of 0.60. The stock has a market cap of $57.85 million, a P/E ratio of -0.77 and a beta of 0.63. The business has a fifty day moving average price of $1.23 and a 200-day moving average price of $1.15. Werewolf Therapeutics has a fifty-two week low of $0.5950 and a fifty-two week high of $4.18.

Institutional Investors Weigh In On Werewolf Therapeutics

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in shares of Werewolf Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 702,558 shares of the company's stock valued at $1,040,000 after purchasing an additional 16,569 shares during the period. Northern Trust Corp grew its stake in shares of Werewolf Therapeutics by 7.3% during the fourth quarter. Northern Trust Corp now owns 244,390 shares of the company's stock valued at $362,000 after acquiring an additional 16,640 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new position in shares of Werewolf Therapeutics in the fourth quarter worth about $26,000. MPM Bioimpact LLC boosted its holdings in Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in Werewolf Therapeutics by 24.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company's stock valued at $162,000 after purchasing an additional 21,500 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company's stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.